Summary

The global digital therapeutics market is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031. The growth of the digital therapeutics market is being driven by the increasing prevalence of chronic diseases, rising demand for personalized and remote patient care, and the growing focus on improving clinical outcomes while reducing healthcare costs. Healthcare providers, payers, and employers are increasingly adopting evidence-based digital therapeutics to prevent, manage, and treat conditions such as diabetes, obesity, cardiovascular diseases, musculoskeletal disorders, insomnia, and mental health disorders through clinically validated software interventions. Furthermore, regulatory and reimbursement support for digital health solutions continues to strengthen. In March 2025, the European Health Data Space (EHDS) Regulation entered into force, establishing a harmonized framework for the secure exchange and secondary use of electronic health data across the European Union, which is expected to facilitate the integration and scalability of digital therapeutics. In addition, continued advances in artificial intelligence (AI), remote patient monitoring, wearable technologies, and interoperable digital health infrastructure are enhancing the personalization, accessibility, and effectiveness of digital therapeutics while supporting value-based healthcare delivery. However, market growth may be constrained by fragmented reimbursement policies across countries, evolving regulatory requirements, concerns regarding data privacy and cybersecurity, limited awareness among healthcare professionals, and the need for robust clinical and real-world evidence to demonstrate long-term therapeutic and economic value. In 2025, the hospitals segment accounted for the largest share of the digital therapeutics market, by end user. By end user, hospitals accounted for the largest share of the digital therapeutics market in 2025. Their leading position is driven by the increasing integration of digital therapeutics into multidisciplinary care pathways for chronic disease management, mental health, rehabilitation, and post-acute care. Hospitals are adopting these solutions to complement conventional therapies, improve patient engagement, support continuous remote monitoring, and enhance treatment adherence beyond inpatient settings. The growing emphasis on value-based care, reducing hospital readmissions, and delivering personalized, data-driven interventions has further accelerated the deployment of digital therapeutics across hospital networks. In addition, the availability of integrated digital health infrastructure, established clinical workflows, and stronger collaboration with technology developers and healthcare providers has enabled hospitals to effectively implement evidence-based digital therapeutic solutions at scale. As healthcare systems continue to prioritize connected care models and long-term disease management, hospitals have maintained their position as the largest end-user segment in the digital therapeutics market. The B2C segment, by sales channel, is expected to register the fastest growth during the forecast period. By sales channel, the B2C (business-to-consumer) segment is expected to be the fastest-growing segment in the digital therapeutics market during the forecast period. This growth is driven by increasing consumer awareness of digital health solutions, rising demand for convenient self-management tools, and growing acceptance of preventive and wellness-focused care. Consumers are increasingly adopting digital therapeutics through mobile applications and connected devices to manage conditions such as obesity, sleep disorders, stress, anxiety, diabetes, and other lifestyle-related diseases without relying solely on traditional healthcare settings. The rapid expansion of smartphone penetration, wearable health technologies, and subscription-based digital health platforms has made these solutions more accessible and affordable for a broader population. Additionally, advancements in artificial intelligence, personalized behavioral coaching, and real-time health insights are improving user engagement and long-term adherence, while direct-to-consumer marketing strategies and expanding digital distribution channels are further accelerating the adoption of B2C digital therapeutics throughout the forecast period. Asia Pacific to witness the highest growth rate during the forecast period. The Asia Pacific region is projected to register the highest growth rate in the digital therapeutics market during the forecast period. This growth is driven by the rising prevalence of chronic diseases, rapid healthcare digitalization, increasing smartphone adoption, and supportive government initiatives promoting digital health infrastructure across the region. Countries such as China, Japan, India, South Korea, Singapore, and Australia are expanding investments in telehealth, remote patient monitoring, artificial intelligence (AI)-enabled healthcare, and digital disease management to improve healthcare accessibility and address the growing burden of diabetes, cardiovascular diseases, obesity, and mental health disorders. Furthermore, the increasing presence of digital health startups, expanding collaborations between healthcare providers and technology companies, and growing reimbursement support for digital health solutions are accelerating the adoption of digital therapeutics across the region. Recent industry developments further reinforce this momentum; in February 2024, TruDoc Healthcare acquired Wellthy Therapeutics, one of Asia’s leading digital therapeutics companies, to strengthen its digital healthcare capabilities across the GCC region while expanding into India, combining Wellthy's clinically validated digital therapeutics platform with TruDoc's virtual primary care and remote healthcare services. This acquisition highlights the increasing strategic investments in digital therapeutics and reinforces Asia Pacific's position as a key hub for innovation and commercialization in digital health. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20% • By Designation - C-level: 35%, Director-level: 25%, and Others: 40% • By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, and Latin America: 2% Key Players in the Digital Therapeutics Market The key players functioning in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), and Sword Health, Inc. (Portugal). Research Coverage: This research report categorizes the digital therapeutics market by offering (software/platforms, therapeutic programs, immersive & interface-based therapeutics), product type (prescription digital therapeutics, non-prescription digital therapeutics), application (treatment & care-related applications, preventive applications), revenue model (subscription-based model, licensing (enterprise/SAAS) model, outcome-/value-based model), sales channel (B2B sales channel, B2C sales channel), end user (healthcare provider, payers, employers, patients/individuals, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies (contracts, partnerships, agreements, product & service launches, mergers, and acquisitions), and recent developments associated with the digital therapeutics market. Competitive analysis of upcoming startups in the digital therapeutics market ecosystem is covered in this report. Reasons to Buy the Report This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market. This report provides insights on:  Analysis of key drivers (rising prevalence of chronic and behavioral health conditions, shift toward value-based and patient-centered care, expansion of smartphone adoption and digital health infrastructure, growing clinical evidence and regulatory recognition), restraints (limited reimbursement and inconsistent payment pathways, regulatory complexity and evolving approval frameworks), opportunities (expansion into new therapeutic areas, integration with AI and personalized medicine, increasing partnerships with pharmaceutical and healthcare organizations), and challenges (sustaining long-term patient engagement and adherence, demonstrating long-term clinical and economic value) influencing the growth of the digital therapeutics market.  Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the digital therapeutics market.  Market Development: Comprehensive information on the lucrative emerging markets, offering, product type, application, revenue model, sales channel, end user, and region.  Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the digital therapeutics market.  Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the digital therapeutics market like Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), Sword Health, Inc. (Portugal).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 39
1.5 LIMITATIONS 40
1.6 STAKEHOLDERS 40
1.7 SUMMARY OF CHANGES 41
2 EXECUTIVE SUMMARY 42
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 42
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46
3 PREMIUM INSIGHTS 48
3.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 48
3.2 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE & COUNTRY 49
3.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT 49
4 MARKET OVERVIEW 50
4.1 INTRODUCTION 50
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 51
4.2.1.1 Rising prevalence of chronic and behavioral health conditions 51
4.2.1.2 Shift toward value-based and patient-centered care 52
4.2.1.3 Expansion of smartphone adoption and digital health infrastructure 53
4.2.1.4 Growing clinical evidence and regulatory recognition 53
4.2.2 RESTRAINTS 54
4.2.2.1 Limited reimbursement and inconsistent payment pathways 54
4.2.2.2 Regulatory complexity and evolving approval frameworks 55
4.2.3 OPPORTUNITIES 55
4.2.3.1 Expansion into new therapeutic areas 55
4.2.3.2 Integration with AI and personalized medicine 56
4.2.3.3 Increasing partnerships with pharmaceutical and healthcare organizations 56
4.2.4 CHALLENGES 57
4.2.4.1 Sustaining long-term patient engagement and adherence 57
4.2.4.2 Demonstrating long-term clinical and economic value 57
4.3 UNMET NEEDS & WHITE SPACES 58
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 58
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 59
5 INDUSTRY TRENDS 61
5.1 PORTER’S FIVE FORCES ANALYSIS 61
5.1.1 BARGAINING POWER OF SUPPLIERS 62
5.1.2 BARGAINING POWER OF BUYERS 62
5.1.3 THREAT OF SUBSTITUTES 62
5.1.4 THREAT OF NEW ENTRANTS 62
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 63
5.2 MACROECONOMIC INDICATORS 63
5.2.1 INTRODUCTION 63
5.2.2 GDP TRENDS & FORECAST 63
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 63
5.3 VALUE CHAIN ANALYSIS 64
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 65
5.3.2 DATA INPUTS & TECHNOLOGY INFRASTRUCTURE 65
5.3.3 PLATFORM DEVELOPMENT & DEPLOYMENT 65
5.3.4 DISTRIBUTION 66
5.3.5 MARKETING & SALES 66
5.3.6 POST-SALES SERVICES 66
5.4 ECOSYSTEM ANALYSIS 66
5.5 PRICING ANALYSIS 68
5.5.1 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS,
BY OFFERING (2025) 68
5.5.2 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS,
BY REGION (2025) 69
5.6 KEY CONFERENCES & EVENTS, 2026–2027 70
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.8 INVESTMENT & FUNDING SCENARIO 71
5.9 CASE STUDY ANALYSIS 72
5.10 IMPACT OF 2025 US TARIFFS ON DIGITAL THERAPEUTICS MARKET 74
5.10.1 INTRODUCTION 74
5.10.2 KEY TARIFF RATES 74
5.10.3 PRICE IMPACT ANALYSIS 75
5.10.4 IMPACT ON COUNTRY/REGION 76
5.10.4.1 US 76
5.10.4.2 Europe 76
5.10.4.3 Asia Pacific 76
5.10.5 IMPACT ON END-USE INDUSTRY 76
5.10.5.1 Healthcare providers 76
5.10.5.2 Payers 77
5.10.5.3 Employers 77
5.10.5.4 Patients/Individuals 77
5.10.5.5 Other end users 77
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS,
AND DIGITAL & AI ADOPTION 78
6.1 KEY EMERGING TECHNOLOGIES 78
6.1.1 SOFTWARE AS A MEDICAL DEVICE (SAMD) 78
6.1.2 MOBILE HEALTH (MHEALTH) APPLICATIONS 78
6.1.3 ARTIFICIAL INTELLIGENCE (AI) & MACHINE LEARNING (ML) 79
6.2 COMPLEMENTARY TECHNOLOGIES 79
6.2.1 REMOTE PATIENT MONITORING (RPM) 79
6.2.2 INTERNET OF MEDICAL THINGS (IOMT) 80
6.3 ADJACENT TECHNOLOGIES 80
6.3.1 ELECTRONIC HEALTH RECORDS (EHR/EMR) 80
6.3.2 DIGITAL DIAGNOSTICS 80
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 81
6.5.1 PATENT PUBLICATION TRENDS FOR DIGITAL THERAPEUTICS MARKET 81
6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 83
6.6 FUTURE APPLICATIONS 85
6.6.1 AI-ENABLED PERSONALIZED THERAPEUTICS & CLINICAL DECISION SUPPORT 86
6.6.2 CONTINUOUS REMOTE CARE & DIGITAL HEALTH ECOSYSTEMS 86
6.6.3 DIGITAL BIOMARKER-DRIVEN PREVENTIVE & PRECISION CARE 86
6.7 IMPACT OF AI/GEN AI ON DIGITAL THERAPEUTICS MARKET 87
6.7.1 INTRODUCTION 87
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL THERAPEUTICS MARKET 88
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 89
6.7.3.1 AI technologies in digital therapeutics 89
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 90
6.7.4.1 Digital health & telehealth market 90
6.7.4.2 Remote patient monitoring (RPM) market 90
6.7.4.3 Electronic health records (EHR/EMR) market 91
6.7.5 USER READINESS & IMPACT ASSESSMENT 91
6.7.5.1 User readiness 91
6.7.5.1.1 User A: Healthcare providers 91
6.7.5.1.2 User B: Payers 91
6.7.5.2 Impact assessment 92
6.7.5.2.1 User A: Healthcare providers 92
6.7.5.2.1.1 Implementation 92
6.7.5.2.1.2 Impact 92
6.7.5.2.2 User B: Payers 92
6.7.5.2.2.1 Implementation 92
6.7.5.2.2.2 Impact 92
7 SUSTAINABILITY & REGULATORY LANDSCAPE 93
7.1 REGIONAL REGULATIONS & COMPLIANCE 93
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
7.1.2 REGULATORY FRAMEWORK 97
7.1.2.1 North America 97
7.1.2.2 Europe 97
7.1.2.3 Asia Pacific 98
7.1.2.4 Latin America 98
7.1.2.5 Middle East & Africa 99
7.1.3 INDUSTRY STANDARDS 99
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 101
8.1 INTRODUCTION 101
8.2 DECISION-MAKING PROCESS 101
8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 101
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
8.3.2 BUYING CRITERIA 102
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 104
8.5.1 UNMET NEEDS 104
8.5.2 END-USER EXPECTATIONS 105
8.6 MARKET PROFITABILITY 106
9 DIGITAL THERAPEUTICS MARKET, BY OFFERING 108
9.1 INTRODUCTION 109
9.2 SOFTWARE/PLATFORMS 109
9.2.1 AI-DRIVEN PLATFORM ARCHITECTURES AND EXPANDING REGULATORY PATHWAYS TO DRIVE MARKET EXPANSION 109
9.3 THERAPEUTIC PROGRAMS 111
9.3.1 EXPANDING FDA CLEARANCES ACROSS NEW INDICATIONS AND MATURING REIMBURSEMENT CODES TO DRIVE PROGRAM ADOPTION 111
9.4 IMMERSIVE & INTERFACE-BASED THERAPEUTICS 112
9.4.1 GROWING CLINICAL EVIDENCE AND NEW REIMBURSEMENT CODES FOR
VR-DELIVERED CARE TO DRIVE SEGMENT GROWTH 112
10 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE 114
10.1 INTRODUCTION 115
10.2 PRESCRIPTION DIGITAL THERAPEUTICS 115
10.2.1 REGULATORY APPROVALS AND GROWING CLINICAL VALIDATION TO ACCELERATE ADOPTION OF PRESCRIPTION DIGITAL THERAPEUTICS 115
10.3 NON-PRESCRIPTION DIGITAL THERAPEUTICS 116
10.3.1 INCREASING CONSUMER ACCESSIBILITY AND DIGITAL HEALTH ADOPTION TO ACCELERATE GROWTH OF NON-PRESCRIPTION DIGITAL THERAPEUTICS 116
11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 118
11.1 INTRODUCTION 119
11.2 TREATMENT & CARE-RELATED APPLICATIONS 119
11.2.1 DIABETES 121
11.2.1.1 Rising global diabetes burden and connected digital care to accelerate adoption of digital therapeutics 121
11.2.2 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 122
11.2.2.1 Rising mental health burden and AI-enabled behavioral care to accelerate adoption of digital therapeutics for CNS disorders 122
11.2.3 SMOKING CESSATION 123
11.2.3.1 Increasing tobacco control initiatives and behavioral interventions to boost adoption 123
11.2.4 CHRONIC RESPIRATORY DISEASES 124
11.2.4.1 Rising burden of chronic respiratory conditions and remote disease management to fuel growth 124
11.2.5 MUSCULOSKELETAL DISORDERS 125
11.2.5.1 Rising burden of musculoskeletal conditions and AI-enabled rehabilitation to support market growth 125
11.2.6 CARDIOVASCULAR DISORDERS 126
11.2.6.1 Growing cardiovascular disease burden and remote cardiac care to contribute to market growth 126
11.2.7 MEDICATION ADHERENCE 127
11.2.7.1 Growing need to improve treatment compliance and long-term outcomes to drive growth 127
11.2.8 SLEEP DISORDERS 128
11.2.8.1 Rising prevalence of sleep disorders and connected sleep care to accelerate adoption of digital therapeutics 128
11.2.9 REHABILITATION & PATIENT CARE 129
11.2.9.1 Digital rehabilitation platforms to transform recovery beyond traditional clinical settings 129
11.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 130
11.2.10.1 Digital therapeutics to expand access to evidence-based addiction treatment and long-term recovery support 130
11.2.11 OTHER TREATMENT & CARE-RELATED APPLICATIONS 131
11.3 PREVENTIVE APPLICATIONS 132
11.3.1 PREDIABETES 134
11.3.1.1 Early risk identification and lifestyle intervention to drive adoption of digital therapeutics for prediabetes 134
11.3.2 OBESITY & WEIGHT MANAGEMENT 135
11.3.2.1 Digital therapeutics to complement GLP-1 therapies and enable sustainable weight management 135
11.3.3 NUTRITION & LIFESTYLE MANAGEMENT 136
11.3.3.1 Personalized nutrition and lifestyle coaching to expand role of digital therapeutics in preventive healthcare 136
11.3.4 OTHER PREVENTIVE APPLICATIONS 137
12 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL 138
12.1 INTRODUCTION 139
12.2 SUBSCRIPTION-BASED MODELS 139
12.2.1 CONTINUOUS CARE DELIVERY AND RECURRING PATIENT ENGAGEMENT TO STRENGTHEN ADOPTION 139
12.3 LICENSING (ENTERPRISE/SAAS) MODELS 140
12.3.1 ENTERPRISE ADOPTION AND SCALABLE CLOUD DEPLOYMENTS TO DRIVE GROWTH OF LICENSING (ENTERPRISE/SAAS) MODELS 140
12.4 OUTCOME-/VALUE-BASED MODELS 141
12.4.1 GROWING SHIFT TOWARD PERFORMANCE-BASED REIMBURSEMENT TO DRIVE ADOPTION OF OUTCOME-/VALUE-BASED MODELS 141
13 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 143
13.1 INTRODUCTION 144
13.2 B2B SALES CHANNELS 144
13.2.1 HEALTHCARE ECOSYSTEM PARTNERSHIPS AND REIMBURSEMENT EXPANSION TO DRIVE B2B LEADERSHIP IN DIGITAL THERAPEUTICS 144
13.3 B2C SALES CHANNELS 145
13.3.1 CONSUMER-CENTRIC DIGITAL HEALTH ADOPTION AND PREVENTIVE CARE TRENDS TO ACCELERATE B2C GROWTH 145
14 DIGITAL THERAPEUTICS MARKET, BY END USER 147
14.1 INTRODUCTION 148
14.2 HEALTHCARE PROVIDERS 148
14.2.1 HOSPITALS 149
14.2.1.1 Expanding digital care delivery to drive hospital adoption of digital therapeutics 149
14.2.2 SPECIALTY CLINICS 150
14.2.2.1 Condition-specific care delivery to accelerate digital therapeutics adoption in specialty clinics 150
14.2.3 DIAGNOSTIC & REHABILITATION CENTERS 151
14.2.3.1 Digital rehabilitation and outcome-focused care to drive adoption in diagnostic & rehabilitation centers 151
14.2.4 OTHER HEALTHCARE PROVIDERS 152
14.3 HEALTHCARE PAYERS 153
14.3.1 PUBLIC PAYERS 154
14.3.1.1 Government-led digital health programs to expand role of digital therapeutics in public healthcare 154
14.3.2 PRIVATE PAYERS 155
14.3.2.1 Outcome-based insurance models and employer health strategies to boost digital therapeutics adoption among private payers 155
14.4 EMPLOYERS 156
14.4.1 GROWING EMPHASIS ON PREVENTIVE HEALTHCARE AND VALUE-BASED EMPLOYEE BENEFITS TO ACCELERATE ADOPTION ACROSS EMPLOYER SEGMENT 156
14.5 PATIENTS/INDIVIDUALS 157
14.5.1 INCREASING PREFERENCE FOR SELF-MANAGED AND PREVENTIVE HEALTHCARE TO DRIVE ADOPTION IN SEGMENT 157
14.6 OTHER END USERS 158
15 DIGITAL THERAPEUTICS MARKET, BY REGION 160
15.1 INTRODUCTION 161
15.2 NORTH AMERICA 161
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 162
15.2.2 US 167
15.2.2.1 Expanding reimbursement, AI-powered care, and chronic disease management to drive digital therapeutics adoption 167
15.2.3 CANADA 172
15.2.3.1 Digital health expansion and public healthcare innovation to support digital therapeutics adoption 172
15.3 EUROPE 176
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 177
15.3.2 GERMANY 181
15.3.2.1 Strong digital health ecosystem and favorable reimbursement to drive digital therapeutics adoption 181
15.3.3 FRANCE 186
15.3.3.1 Digital therapeutics access and reimbursement pathway development to boost market expansion 186
15.3.4 UK 190
15.3.4.1 NHS digital transformation and strong regulatory support to accelerate adoption 190
15.3.5 ITALY 195
15.3.5.1 Healthcare digitalization and chronic disease burden to create growth opportunities for digital therapeutics 195
15.3.6 SPAIN 199
15.3.6.1 Healthcare digitalization and telehealth expansion to drive digital therapeutics adoption 199
15.3.7 REST OF EUROPE 203
15.4 ASIA PACIFIC 208
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 209
15.4.2 CHINA 214
15.4.2.1 Software-driven therapeutics to gain regulatory momentum amid government digital health push 214
15.4.3 JAPAN 219
15.4.3.1 Demographic pressures and regulatory reform to drive cautious digital therapeutics adoption 219
15.4.4 INDIA 223
15.4.4.1 Regulatory formalization and selective capital deployment to shape early-stage growth 223
15.4.5 AUSTRALIA 228
15.4.5.1 Strong digital health ecosystem and telehealth adoption to drive digital therapeutics growth 228
15.4.6 SOUTH KOREA 232
15.4.6.1 Government digital health initiatives and AI innovation to accelerate digital therapeutics adoption 232
15.4.7 REST OF ASIA PACIFIC 237
15.5 LATIN AMERICA 241
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 242
15.5.2 BRAZIL 246
15.5.2.1 Universal healthcare expansion and digital health innovation to drive digital therapeutics demand 246
15.5.3 MEXICO 250
15.5.3.1 Growing public health needs and expanding digital access to support market growth 250
15.5.4 REST OF LATIN AMERICA 255
15.6 MIDDLE EAST & AFRICA 259
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 260
15.6.2 GCC COUNTRIES 264
15.6.2.1 National digital health guidance to accelerate software-based therapeutic adoption 264
15.6.2.2 Saudi Arabia 269
15.6.2.2.1 Vision 2030 digital health guidance to establish formal pathway for software-based therapeutics 269
15.6.2.3 UAE 274
15.6.2.3.1 Digital transformation and healthcare innovation to support digital therapeutics growth 274
15.6.2.4 Rest of Gcc Countries 278
15.6.3 SOUTH AFRICA 283
15.6.3.1 Digital health expansion and high disease burden to create opportunities for digital therapeutics 283
15.6.4 REST OF MIDDLE EAST & AFRICA 287
16 COMPETITIVE LANDSCAPE 293
16.1 OVERVIEW 293
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 293
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET 293
16.3 REVENUE ANALYSIS, 2021–2025 295
16.4 MARKET SHARE ANALYSIS, 2025 296
16.5 BRAND/PRODUCT COMPARISON 299
16.6 COMPANY VALUATION & FINANCIAL METRICS 300
16.6.1 FINANCIAL METRICS 300
16.6.2 COMPANY VALUATION 300
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 301
16.7.1 STARS 301
16.7.2 EMERGING LEADERS 301
16.7.3 PERVASIVE PLAYERS 301
16.7.4 PARTICIPANTS 302
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 303
16.7.5.1 Company footprint 303
16.7.5.2 Region footprint 304
16.7.5.3 Offering footprint 305
16.7.5.4 Application footprint 306
16.7.5.5 Revenue model footprint 307
16.7.5.6 End-user footprint 308
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 309
16.8.1 PROGRESSIVE COMPANIES 309
16.8.2 RESPONSIVE COMPANIES 309
16.8.3 DYNAMIC COMPANIES 309
16.8.4 STARTING BLOCKS 309
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 311
16.8.5.1 Detailed list of key startups/SMEs 311
16.8.5.2 Competitive benchmarking of startups/SMEs 311
16.9 COMPETITIVE SCENARIO 312
16.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 312
16.9.2 DEALS 313
16.9.3 OTHER DEVELOPMENTS 314
17 COMPANY PROFILES 315
17.1 KEY PLAYERS 315
17.1.1 TELADOC HEALTH, INC. 315
17.1.1.1 Business overview 315
17.1.1.2 Products & services offered 316
17.1.1.3 Recent developments 317
17.1.1.3.1 Product launches & enhancements 317
17.1.1.3.2 Deals 318
17.1.1.4 MnM view 319
17.1.1.4.1 Right to win 319
17.1.1.4.2 Strategic choices 319
17.1.1.4.3 Weaknesses & competitive threats 319
17.1.2 NOOM, INC. 320
17.1.2.1 Business overview 320
17.1.2.2 Products & services offered 321
17.1.2.3 Recent developments 321
17.1.2.3.1 Product launches & enhancements 321
17.1.2.3.2 Deals 323
17.1.2.4 MnM view 324
17.1.2.4.1 Right to win 324
17.1.2.4.2 Strategic choices 324
17.1.2.4.3 Weaknesses & competitive threats 324
17.1.3 HINGE HEALTH, INC. 325
17.1.3.1 Business overview 325
17.1.3.2 Products & services offered 326
17.1.3.3 Recent developments 327
17.1.3.3.1 Product launches & enhancements 327
17.1.3.3.2 Deals 328
17.1.3.4 MnM view 329
17.1.3.4.1 Right to win 329
17.1.3.4.2 Strategic choices 329
17.1.3.4.3 Weaknesses & competitive threats 329
17.1.4 OMADA HEALTH INC. 330
17.1.4.1 Business overview 330
17.1.4.2 Products & services offered 331
17.1.4.3 Recent Developments 332
17.1.4.3.1 Product Launches & Enhancements 332
17.1.4.3.2 Deals 333
17.1.4.4 MnM view 334
17.1.4.4.1 Right to win 334
17.1.4.4.2 Strategic choices 334
17.1.4.4.3 Weaknesses & competitive threats 334
17.1.5 DARIOHEALTH CORP. 335
17.1.5.1 Business overview 335
17.1.5.2 Products & services offered 336
17.1.5.3 Recent developments 337
17.1.5.3.1 Product launches & enhancements 337
17.1.5.3.2 Deals 338
17.1.5.4 MnM view 338
17.1.5.4.1 Right to win 338
17.1.5.4.2 Strategic choices 339
17.1.5.4.3 Weaknesses & competitive threats 339
17.1.6 SWORD HEALTH, INC. 340
17.1.6.1 Business overview 340
17.1.6.2 Products & services offered 341
17.1.6.3 Recent developments 342
17.1.6.3.1 Product launches & enhancements 342
17.1.6.3.2 Deals 342
17.1.7 RESMED 344
17.1.7.1 Business overview 344
17.1.7.2 Products & services offered 345
17.1.7.3 Recent developments 346
17.1.7.3.1 Deals 346
17.1.8 VIRTA HEALTH CORP. 347
17.1.8.1 Business overview 347
17.1.8.2 Products & services offered 348
17.1.8.3 Recent developments 349
17.1.8.3.1 Product launches & enhancements 349
17.1.8.3.2 Deals 349
17.1.9 WELLDOC, INC. 350
17.1.9.1 Business overview 350
17.1.9.2 Products & services offered 351
17.1.9.3 Recent developments 351
17.1.9.3.1 Product launches & enhancements 351
17.1.9.3.2 Deals 352
17.1.10 CLICK THERAPEUTICS, INC. 354
17.1.10.1 Business overview 354
17.1.10.2 Products & services offered 355
17.1.10.3 Recent developments 356
17.1.10.3.1 Product launches & enhancements 356
17.1.10.3.2 Deals 357
17.1.10.3.3 Other developments 358
17.1.11 SIDEKICK HEALTH 359
17.1.11.1 Business overview 359
17.1.11.2 Products & services offered 359
17.1.11.3 Recent developments 361
17.1.11.3.1 Product launches & enhancements 361
17.1.11.3.2 Deals 362
17.1.12 AKILI, INC. 363
17.1.12.1 Business overview 363
17.1.12.2 Products & services offered 364
17.1.13 APPLIEDVR, INC. 365
17.1.13.1 Business overview 365
17.1.13.2 Products & services offered 366
17.1.13.3 Recent developments 366
17.1.13.3.1 Deals 366
17.1.14 WELLTHY THERAPEUTICS PVT. LTD. 367
17.1.14.1 Business overview 367
17.1.14.2 Products & services offered 368
17.1.15 HEADSPACE INC. 369
17.1.15.1 Business overview 369
17.1.15.2 Products & services offered 370
17.1.15.2.1 Product launches & enhancements 371
17.1.16 LARK TECHNOLOGIES, INC. 372
17.1.16.1 Business overview 372
17.1.16.2 Products & services offered 372
17.1.17 XRHEALTH 374
17.1.17.1 Business overview 374
17.1.17.2 Products & services offered 374
17.1.17.3 Recent developments 376
17.1.17.3.1 Product launches 376
17.1.17.3.2 Deals 376
17.1.18 AMALGAM RX, INC. 378
17.1.18.1 Business overview 378
17.1.18.2 Products & services offered 379
17.1.18.3 Recent developments 379
17.1.18.3.1 Deals 379
17.1.19 APTAR DIGITAL HEALTH 380
17.1.19.1 Business overview 380
17.1.19.2 Products & services offered 382
17.1.19.3 Recent developments 382
17.1.19.3.1 Deals 382
17.1.20 CANARY HEALTH 384
17.1.20.1 Business overview 384
17.1.20.2 Products & services offered 384
17.1.20.3 Recent developments 385
17.1.20.3.1 Deals 385
17.2 START-UP/SME PLAYERS 386
17.2.1 FREESPIRA 386
17.2.2 MINDABLE HEALTH GMBH 387
17.2.3 GET.ON INSTITUT FÜR ONLINE GESUNDHEITSTRAININGS GMBH 388
17.2.4 COGNIFIT INC. 389
17.2.5 2MORROW INC. 390
18 RESEARCH METHODOLOGY 391
18.1 RESEARCH APPROACH 391
18.1.1 SECONDARY RESEARCH 392
18.1.1.1 Key data from secondary sources 393
18.1.2 PRIMARY RESEARCH 393
18.1.2.1 Primary sources 394
18.1.2.2 Key data from primary sources 395
18.1.2.3 Breakdown of primaries 395
18.1.2.4 Insights from primary experts 396
18.2 RESEARCH METHODOLOGY DESIGN 396
18.3 MARKET SIZE ESTIMATION 398
18.4 DATA TRIANGULATION 403
18.5 MARKET SHARE ESTIMATION 404
18.6 STUDY ASSUMPTIONS 404
18.7 RESEARCH LIMITATIONS 405
18.7.1 METHODOLOGY-RELATED LIMITATIONS 405
18.8 RISK ASSESSMENT 405
19 APPENDIX 406
19.1 DISCUSSION GUIDE 406
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411
19.3 CUSTOMIZATION OPTIONS 413
19.4 RELATED REPORTS 413
19.5 AUTHOR DETAILS 414

ページTOPに戻る

List of Tables/Graphs

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 39.
TABLE 2 DIGITAL THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 62.
TABLE 3 DIGITAL THERAPEUTICS MARKET: ROLE IN ECOSYSTEM 67.
TABLE 4 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY OFFERING (2025) 69.
TABLE 5 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY REGION (2025) 69.
TABLE 6 DIGITAL THERAPEUTICS MARKET: KEY CONFERENCES & EVENTS 2026–2027 70.
TABLE 7 CASE 1: DIGITAL THERAPEUTICS FOR IMPROVING BALANCE AND REDUCING FALL RISK 72.
TABLE 8 CASE 2: DIGITAL THERAPEUTICS FOR WEIGHT MANAGEMENT AND BEHAVIOR CHANGE 73.
TABLE 9 CASE 3: PRESCRIPTION DIGITAL THERAPEUTICS FOR SCHIZOPHRENIA MANAGEMENT 73.
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 74.
TABLE 11 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DIGITAL THERAPEUTICS MARKET 83.
TABLE 12 DIGITAL THERAPEUTICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 85.
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94.
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95.
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96.
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96.
TABLE 18 REGULATORY SCENARIO OF NORTH AMERICA 97.
TABLE 19 REGULATORY SCENARIO OF EUROPE 97.
TABLE 20 REGULATORY SCENARIO OF ASIA PACIFIC 98.
TABLE 21 REGULATORY SCENARIO OF LATIN AMERICA 98.
TABLE 22 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 99.
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 102.
TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 103.
TABLE 25 UNMET NEEDS IN DIGITAL THERAPEUTICS MARKET 105.
TABLE 26 END-USER EXPECTATIONS IN THE DIGITAL THERAPEUTICS MARKET 106.
TABLE 27 DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 109.
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR SOFTWARE/PLATFORMS, BY REGION, 2024–2031 (USD MILLION) 110.
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR THERAPEUTIC PROGRAMS, BY REGION, 2024–2031 (USD MILLION) 112.
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR IMMERSIVE & INTERFACE-BASED THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION) 113.
TABLE 31 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 115.
TABLE 32 PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 33 NON-PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 117.
TABLE 34 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 119.
TABLE 35 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 120.
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 121.
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 122.
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2024–2031 (USD MILLION) 123.
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2024–2031 (USD MILLION) 124.
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2024–2031 (USD MILLION) 125.
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 42 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR SLEEP DISORDERS, BY REGION, 2024–2031 (USD MILLION) 129.
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2024–2031 (USD MILLION) 130.
TABLE 46 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 47 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 132.
TABLE 48 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 133.
TABLE 49 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 133.
TABLE 50 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 51 DIGITAL THERAPEUTICS MARKET FOR OBESITY & WEIGHT MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 135.
TABLE 52 DIGITAL THERAPEUTICS MARKET FOR NUTRITION & LIFESTYLE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 53 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 54 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 139.
TABLE 55 DIGITAL THERAPEUTICS MARKET FOR SUBSCRIPTION-BASED MODELS, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 56 DIGITAL THERAPEUTICS MARKET FOR LICENSING (ENTERPRISE/SAAS) MODELS, BY REGION, 2024–2031 (USD MILLION) 141.
TABLE 57 DIGITAL THERAPEUTICS MARKET FOR OUTCOME-/VALUE-BASED MODELS, BY REGION, 2024–2031 (USD MILLION) 142.
TABLE 58 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 144.
TABLE 59 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNELS, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 60 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNELS, BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 61 DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 148.
TABLE 62 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 149.
TABLE 63 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 149.
TABLE 64 DIGITAL THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 150.
TABLE 65 DIGITAL THERAPEUTICS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 151.
TABLE 66 DIGITAL THERAPEUTICS MARKET FOR DIAGNOSTIC & REHABILITATION CENTERS, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 67 DIGITAL THERAPEUTICS MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 153.
TABLE 68 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 154.
TABLE 69 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY REGION, 2024–2031 (USD MILLION) 154.
TABLE 70 DIGITAL THERAPEUTICS MARKET FOR PUBLIC PAYERS, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 71 DIGITAL THERAPEUTICS MARKET FOR PRIVATE PAYERS, BY REGION, 2024–2031 (USD MILLION) 156.
TABLE 72 DIGITAL THERAPEUTICS FOR EMPLOYERS, BY REGION, 2024–2031 (USD MILLION) 157.
TABLE 73 DIGITAL THERAPEUTICS FOR PATIENTS/INDIVIDUALS, BY REGION, 2024–2031 (USD MILLION) 158.
TABLE 74 DIGITAL THERAPEUTICS FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 75 DIGITAL THERAPEUTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 161.
TABLE 76 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 77 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 163.
TABLE 78 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 163.
TABLE 79 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 164.
TABLE 80 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 164.
TABLE 81 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 165.
TABLE 82 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 165.
TABLE 83 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 165.
TABLE 84 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 166.
TABLE 85 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 166.
TABLE 86 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 167.
TABLE 87 US: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 168.
TABLE 88 US: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 168.
TABLE 89 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 168.
TABLE 90 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 169.
TABLE 91 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 170.
TABLE 92 US: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 170.
TABLE 93 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 170.
TABLE 94 US: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 171.
TABLE 95 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 171.
TABLE 96 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 171.
TABLE 97 CANADA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 172.
TABLE 98 CANADA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 173.
TABLE 99 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173.
TABLE 100 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 174.
TABLE 101 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 174.
TABLE 102 CANADA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 175.
TABLE 103 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 175.
TABLE 104 CANADA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 175.
TABLE 105 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 176.
TABLE 106 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 176.
TABLE 107 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 108 EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 178.
TABLE 109 EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 178.
TABLE 110 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 178.
TABLE 111 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 179.
TABLE 112 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 179.
TABLE 113 EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 180.
TABLE 114 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 180.
TABLE 115 EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 180.
TABLE 116 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 181.
TABLE 117 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 181.
TABLE 118 GERMANY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 182.
TABLE 119 GERMANY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 182.
TABLE 120 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 183.
TABLE 121 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 183.
TABLE 122 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 184.
TABLE 123 GERMANY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 184.
TABLE 124 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 184.
TABLE 125 GERMANY: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 185.
TABLE 126 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 185.
TABLE 127 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 185.
TABLE 128 FRANCE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 186.
TABLE 129 FRANCE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 187.
TABLE 130 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 187.
TABLE 131 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 188.
TABLE 132 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 188.
TABLE 133 FRANCE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 189.
TABLE 134 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 189.
TABLE 135 FRANCE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 189.
TABLE 136 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 190.
TABLE 137 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 190.
TABLE 138 UK: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 191.
TABLE 139 UK: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 191.
TABLE 140 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 192.
TABLE 141 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 142 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 193.
TABLE 143 UK: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 193.
TABLE 144 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 193.
TABLE 145 UK: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 194.
TABLE 146 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 194.
TABLE 147 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 194.
TABLE 148 ITALY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 195.
TABLE 149 ITALY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 196.
TABLE 150 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 196.
TABLE 151 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 152 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197.
TABLE 153 ITALY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 198.
TABLE 154 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 198.
TABLE 155 ITALY: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 198.
TABLE 156 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 199.
TABLE 157 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 199.
TABLE 158 SPAIN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 200.
TABLE 159 SPAIN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 200.
TABLE 160 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 200.
TABLE 161 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 201.
TABLE 162 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 201.
TABLE 163 SPAIN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 202.
TABLE 164 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 202.
TABLE 165 SPAIN: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 202.
TABLE 166 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 203.
TABLE 167 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 203.
TABLE 168 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 204.
TABLE 169 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 204.
TABLE 170 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 205.
TABLE 171 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 205.
TABLE 172 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 206.
TABLE 173 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 206.
TABLE 174 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 206.
TABLE 175 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 207.
TABLE 176 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 207.
TABLE 177 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 178 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 179 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 210.
TABLE 180 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 211.
TABLE 181 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 211.
TABLE 182 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 212.
TABLE 183 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 212.
TABLE 184 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 213.
TABLE 185 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 213.
TABLE 186 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 213.
TABLE 187 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 188 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 189 CHINA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 215.
TABLE 190 CHINA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 215.
TABLE 191 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 216.
TABLE 192 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 216.
TABLE 193 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 217.
TABLE 194 CHINA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 217.
TABLE 195 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 217.
TABLE 196 CHINA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 218.
TABLE 197 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 198 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 199 JAPAN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 219.
TABLE 200 JAPAN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 220.
TABLE 201 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 220.
TABLE 202 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 203 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 221.
TABLE 204 JAPAN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 222.
TABLE 205 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 222.
TABLE 206 JAPAN: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 222.
TABLE 207 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 223.
TABLE 208 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 223.
TABLE 209 INDIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 224.
TABLE 210 INDIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 224.
TABLE 211 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 225.
TABLE 212 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 225.
TABLE 213 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 226.
TABLE 214 INDIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 226.
TABLE 215 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 226.
TABLE 216 INDIA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 227.
TABLE 217 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 227.
TABLE 218 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 227.
TABLE 219 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 228.
TABLE 220 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 229.
TABLE 221 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 229.
TABLE 222 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 230.
TABLE 223 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 230.
TABLE 224 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 231.
TABLE 225 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 231.
TABLE 226 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 231.
TABLE 227 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 232.
TABLE 228 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 232.
TABLE 229 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 233.
TABLE 230 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 233.
TABLE 231 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 234.
TABLE 232 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 234.
TABLE 233 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 235.
TABLE 234 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 235.
TABLE 235 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 235.
TABLE 236 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 236.
TABLE 237 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 236.
TABLE 238 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 237.
TABLE 239 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 238.
TABLE 240 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 238.
TABLE 241 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 238.
TABLE 242 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 239.
TABLE 243 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 239.
TABLE 244 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 240.
TABLE 245 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 240.
TABLE 246 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 240.
TABLE 247 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 241.
TABLE 248 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 241.
TABLE 249 LATIN AMERICA: DIGITAL THERAPEUTUCS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 242.
TABLE 250 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 243.
TABLE 251 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 243.
TABLE 252 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243.
TABLE 253 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 244.
TABLE 254 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 244.
TABLE 255 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 245.
TABLE 256 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 245.
TABLE 257 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 245.
TABLE 258 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 246.
TABLE 259 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 246.
TABLE 260 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 247.
TABLE 261 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 247.
TABLE 262 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 247.
TABLE 263 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 264 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 265 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 249.
TABLE 266 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 249.
TABLE 267 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 249.
TABLE 268 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 250.
TABLE 269 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 250.
TABLE 270 MEXICO: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 251.
TABLE 271 MEXICO: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 251.
TABLE 272 MEXICO: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252.
TABLE 273 MEXICO: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 252.
TABLE 274 MEXICO: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 253.
TABLE 275 MEXICO: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 253.
TABLE 276 MEXICO: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 253.
TABLE 277 MEXICO: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 254.
TABLE 278 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 279 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 280 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 255.
TABLE 281 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 256.
TABLE 282 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256.
TABLE 283 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257.
TABLE 284 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257.
TABLE 285 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024–2031 (USD MILLION) 258.
TABLE 286 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024–2031 (USD MILLION) 258.
FIGURE 1 DIGITAL THERAPEUTICS MARKET SEGMENTATION & REGIONAL SCOPE 37.
FIGURE 2 MARKET SCENARIO 42.
FIGURE 3 GLOBAL DIGITAL THERAPEUTICS MARKET, 2024–2031 43.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2023–2026 43.
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL THERAPEUTICS MARKET 44.
FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL THERAPEUTICS MARKET, 2026–2031 45.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL THERAPEUTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46.
FIGURE 8 RISING DEMAND FOR DIGITAL HEALTHCARE AND PATIENT-CENTRIC CARE TO DRIVE GROWTH IN DIGITAL THERAPEUTICS MARKET 48.
FIGURE 9 PRESCRIPTION DIGITAL THERAPEUTICS IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 49.
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 49.
FIGURE 11 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51.
FIGURE 12 DIGITAL THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 61.
FIGURE 13 DIGITAL THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 65.
FIGURE 14 DIGITAL THERAPEUTICS MARKET: ECOSYSTEM ANALYSIS 67.
FIGURE 15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71.
FIGURE 17 PATENT PUBLICATION TRENDS IN DIGITAL THERAPEUTICS MARKET, 2015–2026 82.
FIGURE 18 JURISDICTION & TOP APPLICANT ANALYSIS FOR DIGITAL THERAPEUTICS MARKET 83.
FIGURE 19 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DIGITAL THERAPEUTICS MARKET (JANUARY 2015–JULY 2026) 84.
FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL THERAPEUTICS ACROSS INDUSTRIES 88.
FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 90.
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 102.
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 103.
FIGURE 24 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 162.
FIGURE 25 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET SNAPSHOT 209.
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2021–2025 296.
FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET (2025) 297.
FIGURE 28 DIGITAL THERAPEUTICS MARKET: BRAND COMPARATIVE ANALYSIS 299.
FIGURE 29 EV/EBITDA OF KEY VENDORS 300.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 300.
FIGURE 31 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 302.
FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPANY FOOTPRINT 303.
FIGURE 33 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 310.
FIGURE 34 TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2025) 316.
FIGURE 35 HINGE HEALTH, INC.: COMPANY SNAPSHOT (2025) 326.
FIGURE 36 OMADA HEALTH INC.: COMPANY SNAPSHOT (2025) 331.
FIGURE 37 DARIOHEALTH CORP.: COMPANY SNAPSHOT (2025) 336.
FIGURE 38 RESMED: COMPANY SNAPSHOT (2025) 345.
FIGURE 39 APTAR DIGITAL HEALTH: COMPANY SNAPSHOT (2025) 381.
FIGURE 40 RESEARCH DESIGN 391.
FIGURE 41 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 395.
FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 397.
FIGURE 43 BOTTOM-UP APPROACH 398.
FIGURE 44 TOP-DOWN APPROACH 399.
FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF DIGITAL THERAPEUTICS INDUSTRY 400.
FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 400.
FIGURE 47 DATA TRIANGULATION METHODOLOGY 403.